Reported Sep 23, 2026 · Ongoing
Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg,…
Vitruvias Therapeutics Inc.
Risk not classifiedThe agency has not ranked the risk yet — treat the notice as a caution.What you should do
Stop using the affected lot and contact the recalling firm for the return or refund process. Check the FDA enforcement report for lot-level detail.
Firm contact: VITRUVIAS THERAPEUTICS INC · 778 N Dean Rd Ste 600 · Auburn, AL · 36830-4318
Is this the product you have?
- Thyroid Tablets, USP, 1/2 Grain (30 mg)
- Each tablet contains
levothyroxine (T4) 19 mcgliothyronine (T3) 4.5 mcg100 TabletsRx only
- Distributed byVitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00
- Lot codes and dates
- Lot # 504950
- Exp Date09/30/2026
Where it was sold
- Nationwide
Why it was recalled
Superpotent Drug: Testing showed an upward T3 assay trend.
The agency has not ranked the risk yet — treat the notice as a caution.
Want the full recall guide?
The guide adds the identifying codes laid out for scanning, symptoms to watch for, a timeline, and news coverage of this recall.
Free recall alerts
Get alerted about new Vitruvias Therapeutics Inc. recalls
One email when a matching recall is published. No account, no cost, unsubscribe in one click.
We email you about recalls and nothing else. Every send has a one-click unsubscribe, and you can change your preferences any time without an account.